Trevi Therapeutics (TRVI) to Release Quarterly Earnings on Tuesday

Trevi Therapeutics (NASDAQ:TRVI) is expected to issue its quarterly earnings data before the market opens on Tuesday, March 18th. Analysts expect the company to announce earnings of ($0.12) per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

Trevi Therapeutics Trading Up 7.3 %

Shares of TRVI stock opened at $6.75 on Monday. The stock has a market cap of $518.85 million, a P/E ratio of -15.34 and a beta of 0.90. The stock has a 50 day simple moving average of $4.35 and a 200 day simple moving average of $3.63. Trevi Therapeutics has a 1 year low of $2.30 and a 1 year high of $7.39.

Analyst Upgrades and Downgrades

TRVI has been the subject of several recent research reports. Oppenheimer boosted their price target on Trevi Therapeutics from $12.00 to $20.00 and gave the company an “outperform” rating in a research note on Tuesday, March 11th. Raymond James upgraded Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and boosted their price target for the company from $9.00 to $29.00 in a research note on Monday, March 10th. D. Boral Capital reiterated a “buy” rating and issued a $21.00 price target on shares of Trevi Therapeutics in a research note on Friday, March 7th. HC Wainwright boosted their price objective on shares of Trevi Therapeutics from $7.50 to $12.50 and gave the company a “buy” rating in a research report on Monday, March 10th. Finally, Needham & Company LLC boosted their price objective on shares of Trevi Therapeutics from $8.00 to $25.00 and gave the company a “buy” rating in a research report on Monday, March 10th. Seven analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $15.94.

Insider Transactions at Trevi Therapeutics

In other news, insider Farrell Simon sold 81,313 shares of the company’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $6.75, for a total transaction of $548,862.75. Following the completion of the transaction, the insider now directly owns 76,900 shares in the company, valued at approximately $519,075. This represents a 51.39 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 24.37% of the company’s stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.